Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Vanessa García-Morales"'
Autor:
Vicente Villanueva, Daniel Santos‐Carrasco, Pablo Cabezudo‐García, Asier Gómez‐Ibáñez, Mercedes Garcés, Pedro Serrano‐Castro, Maria D. Castro‐Vilanova, Débora Sayas, Francisco J. Lopez‐Gonzalez, Xiana Rodríguez‐Osorio, Gustavo Torres‐Gaona, Rosa A. Saiz‐Diaz, Kevin G. Hampel, Meritxell Martinez‐Ferri, Maria J. Aguilar‐Amat, Blanca Mercedes‐Alvarez, Vanessa García‐Morales, Ana delVillar‐Igea, Andreu Massot‐Tarrús, Juan J. Rodríguez‐Uranga
Publikováno v:
Epilepsia Open, Vol 8, Iss 3, Pp 918-929 (2023)
Abstract Objective This study investigated early, real‐world outcomes with cenobamate (CNB) in a large series of patients with highly drug‐resistant epilepsy within a Spanish Expanded Access Program (EAP). Method This was a multicenter, retrospec
Externí odkaz:
https://doaj.org/article/f8b37a01407e41bfbb4bb79fdd84497c
Autor:
María Eugenia García-García, Iñigo Garamendi-Ruiz, Vicente Bertol-Alegre, Ainhoa Marinas-Alejo, Marta Agúndez-Sarasola, José Antonio Oliván-Usieto, A.B. Gago-Veiga, García-Gomara Mj, Sonia Santos-Lasaosa, Mauri-Llerda Ja, Juan Carlos Gómez-Esteban, Inés Escalza-Cortina, Carolina Arcos-Sánchez, Eliana Rueda-Mena, Vanesa Garayoa-Irigoyen, Leyre Díaz de Cerio Julián, Elena Muñoz-Fargas, Vanessa García-Morales, María De Toledo-Heras, Irene García-Morales
Publikováno v:
Epileptic Disorders. 18:173-180
Perampanel, a non-competitive antagonist of the α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptors, is the most recent antiepileptic drug available in Spain, marketed in January 2014. It was initially approved by the European Medicines